Arca Biopharma Stock Beneish M Score
| ABIO Stock | USD 3.25 0.04 1.25% |
ARCA | Beneish M Score |
At this time, it appears that ARCA Biopharma is an unlikely manipulator. The earnings manipulation may begin if ARCA Biopharma's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by ARCA Biopharma executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of ARCA Biopharma's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-45.55
Beneish M Score - Unlikely Manipulator
ARCA Biopharma Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if ARCA Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 157.3 K | 165.6 K |
|
| |||||
| Total Assets | 34.9 M | 37.9 M |
|
| |||||
| Total Current Assets | 29 M | 37.6 M |
|
| |||||
| Non Current Assets Total | 255.5 K | 269 K |
|
| |||||
| Property Plant Equipment | 314.6 K | 331.2 K |
|
| |||||
| Depreciation And Amortization | 105.5 K | 111 K |
|
| |||||
| Selling General Administrative | 7.2 M | 6.3 M |
|
| |||||
| Total Current Liabilities | 605.1 K | 637 K |
|
| |||||
| Short Term Debt | 72.2 K | 76 K |
|
| |||||
| Long Term Investments | 1.9 M | 2.1 M |
|
| |||||
| Gross Profit Margin | 1.02 | 1.08 |
|
|
ARCA Biopharma Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between ARCA Biopharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards ARCA Biopharma in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find ARCA Biopharma's degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About ARCA Biopharma Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
ARCA Biopharma Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as ARCA Biopharma. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 8.5M | 50.4M | 54.9M | 43.1M | 37.9M | 34.9M | |
| Total Current Assets | 8.5M | 50.0M | 54.4M | 42.7M | 37.6M | 29.0M | |
| Net Debt | (8.3M) | (48.7M) | (53.0M) | (42.2M) | (37.2M) | (35.3M) | |
| Operating Income | (5.8M) | (9.8M) | (19.3M) | (10.6M) | (7.3M) | (7.7M) | |
| Investments | 3.1M | (4K) | (19K) | (43K) | (2K) | 0.0 |
About ARCA Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARCA Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARCA Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARCA Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ARCA Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ARCA Biopharma's short interest history, or implied volatility extrapolated from ARCA Biopharma options trading.
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against ARCA Stock
| 0.84 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.65 | PFE | Pfizer Inc Sell-off Trend | PairCorr |
| 0.46 | KZR | Kezar Life Sciences Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ARCA Biopharma Piotroski F Score and ARCA Biopharma Altman Z Score analysis. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.11) | Return On Equity (0.14) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.